ABCG2 and cancer: Results showed that erdafitinib reverses multidrug resistance mediated by ABCB1 (Table 2), but not by ABCG2 (Table 3), in human cancer cell lines at subtoxic concentrations (<1 μM) and in a concentration-dependent manner.